ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients

(2021) Subrata Deb et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

(2021) Subrata Deb et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures

(2020) Yixuan Wang et al.   JOURNAL OF MEDICAL VIROLOGY

Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses

(2020) Jieliang Chen   MICROBES AND INFECTION

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

(2020) Duxin Sun   AAPS Journal

Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING

(2020) Yan-Ni Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

What do we know about remdesivir drug interactions?

(2020) Katherine Yang   CTS-Clinical and Translational Science

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment options for COVID-19: The reality and challenges

(2020) Shio-Shin Jean et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

(2020) Jason D. Goldman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir: Review of pharmacology, pre‐clinical data and emerging clinical experience for COVID‐19

(2020) Sarah CJ Jorgensen et al.   PHARMACOTHERAPY

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

(2020) Alfonso J. Rodriguez-Morales et al.   Travel Medicine and Infectious Disease

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

(2020) Kuldeep Dhama et al.   Human Vaccines & Immunotherapeutics

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

(2020) Richard T. Eastman et al.   ACS Central Science

Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear

(2020) Nathan D. Grubaugh et al.   CELL

Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors

(2020) Emiel Leegwater et al.   CLINICAL INFECTIOUS DISEASES

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects

(2020) Rita Humeniuk et al.   CTS-Clinical and Translational Science

Natural Products as Modulators of CES1 Activity

(2020) Yuli Qian et al.   DRUG METABOLISM AND DISPOSITION

Liver injury in remdesivir-treated COVID-19 patients

(2020) Rosa Zampino et al.   Hepatology International

Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19

(2020) Massimo Tempestilli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening

(2020) Cristina Adriana Dehelean et al.   Journal of Clinical Medicine

Remdesivir, a remedy or a ripple in severe COVID-19?

(2020) Sheila A. Doggrell   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

(2020) Sawittree Sahakijpijarn et al.   Pharmaceutics

Pharmacogenomics of COVID-19 therapies

(2020) Takuto Takahashi et al.   npj Genomic Medicine

Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis

(2020) Fritz Sörgel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carboxylesterase Inhibitors: An Update

(2018) Li-Wei Zou et al.   CURRENT MEDICINAL CHEMISTRY

Refinement of In Vitro Methods for Identification of Aldehyde Oxidase Substrates Reveals Metabolites of Kinase Inhibitors

(2018) Ryan A. Dick   DRUG METABOLISM AND DISPOSITION

Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment

(2018) Randall K. Hoover et al.   JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Vivo Drug-Drug Interaction Study of the Effects of Ivermectin and Oxantel Pamoate on Tribendimidine

(2018) Anna Neodo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity

(2014) Sanna R Rijpma et al.   MALARIA JOURNAL

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?

(2013) S. Casey Laizure et al.   PHARMACOTHERAPY

Human cytochromes P450 in health and disease

(2013) D. W. Nebert et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Oral and inhaled corticosteroids: Differences in P-glycoprotein (ABCB1) mediated efflux

(2012) Andrew Crowe et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Carboxylesterase inhibitors

(2011) M. Jason Hatfield et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

(2010) David R. Luke et al.   JOURNAL OF PHARMACEUTICAL SCIENCES